Key Documents

View All Documentation

SML0492

Zanamivir

Name: Zanamivir
Brand: SIGMA

≥98% (HPLC), Influenza viral neuraminidase inhibitor, powder

Synonym(s):

4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid, 4-Guanidino-Neu5Ac2en

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₁₂H₂₀N₄O₇

CAS Number:

139110-80-8

Molecular Weight:

332.31

UNSPSC Code:

12352200

PubChem Substance ID:

329825442

NACRES:

NA.77

MDL number:

MFCD00866966

Assay:

≥98% (HPLC)

Form:

powder

Quality level:

100

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

Product Name

Zanamivir, ≥98% (HPLC)

Quality Level

100

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D +30 to +40°, c = 1 in H₂O

color

white to beige

solubility

H₂O: 10 mg/mL, clear

storage temp.

room temp

SMILES string

CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O

InChI

1S/C12H20N4O7/c1-4(18)15-8-5(16-12(13)14)2-7(11(21)22)23-10(8)9(20)6(19)3-17/h2,5-6,8-10,17,19-20H,3H2,1H3,(H,15,18)(H,21,22)(H4,13,14,16)/t5-,6+,8+,9+,10+/m0/s1

InChI key

ARAIBEBZBOPLMB-UFGQHTETSA-N

Description

Application

Zanamivir has been used:

as a neuraminidase inhibitor to study its effects on influenza A virus (IAV) like particles
as a neuraminidase inhibitor to study its effects on lipopolysaccharide (LPS)-mediated pathology in sepsis
as an antiviral to study its effects on influenza B virus by plaque reduction assay

Biochem/physiol Actions

Zanamivir is an influenza viral neuraminidase inhibitor.

Zanamivir exhibits therapeutic effects against influenza caused by influenza virus A and B.

Still not finding the right product?

Explore all of our products under Zanamivir

pictograms

GHS07

signalword

Warning

hcodes

H302,H315,H319,H335

pcodes

P261 - P264 - P270 - P301 + P312 - P302 + P352 - P305 + P351 + P338

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

0000278857

0000225609

0000225608

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Inhibiting influenza virus transmission using a broadly acting neuraminidase that targets host sialic acids in the upper respiratory tract.

Mila B Ortigoza et al.

mBio, 15(2), e0220323-e0220323 (2024-01-11)

The ongoing transmission of influenza A viruses (IAV) for the past century continues to be a burden to humans. IAV binds terminal sialic acids (SA) of sugar molecules present within the upper respiratory tract (URT) in order to successfully infect

Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments.

Carl J Heneghan et al.

BMJ (Clinical research ed.), 348, g2547-g2547 (2014-05-09)

To describe the potential benefits and harms of zanamivir. Systematic review of clinical study reports of randomised placebo controlled trials and regulatory information Clinical study reports, trial registries, electronic databases, regulatory archives, and correspondence with manufacturers. Randomised placebo controlled trials

Synthetic approaches to the neuraminidase inhibitors zanamivir (Relenza) and oseltamivir phosphate (Tamiflu) for the treatment of influenza.

Javier Magano

Chemical reviews, 109(9), 4398-4438 (2009-06-23)

View All Related Papers